CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Tiopronin 1g per day +2 moredrug
Likely dose
Tiopronin 1g per dayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02125721
NCT02125721Phase 4Completed
CompareCT.gov

Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria

NYU Langone Health·interventional·Posted Apr 29, 2014·Updated Aug 23, 2021

In Brief

A Phase 4 clinical trial evaluating Tiopronin 1g per day, Tiopronin 2g per day, and 1 other intervention for Cystinuria. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the effect of escalating doses of cystine biding thiol drugs, including tiopronin and d-penicillamine, on the urinary cystine capacity, which is a measure of the amount of cystine in the urine, in patients with cystinuria. The overall goal will be to help guide therapy and ultimately minimize unnecessary side effects caused by larger doses.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystinuria
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2014
Enrollment StartJun 1, 2012
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 12.2 years ago

Interventions

Tiopronin 1g per daydrug

500mg PO BID x 7 days

Tiopronin 2g per daydrug

1g PO BID x 7 days

Tiopronin 3g per daydrug

1.5g PO BID x 7 days